Evidence-based·Updated November 19, 2026·How we grade evidence

Thymosin Alpha-1

PeptideResearch peptide

Thymosin alpha-1 has real human trial data, mostly from outside the US, but the largest and best-designed trials were negative: it did not lower 28-day deaths in 1,089 adults with sepsis or prevent infected pancreatic necrosis in 508 patients with severe pancreatitis. Smaller studies in hepatitis B, cancer and COVID-19 suggest possible benefits that have not been confirmed. It is not approved in the US.

Taking Thymosin Alpha-1 with other supplements or medications?Check your whole list for interactions. Free, no account.

Research compound: not an approved drug or dietary supplement

This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only. Talk to a clinician before considering it.

Quick decision guide

May help most

No one outside a clinical trial in the US. In trials it has been studied in adults with chronic hepatitis B, sepsis, severe pancreatitis, some cancers and COVID-19

Common dosing range

No approved or established dose in the US. Trials gave 1.6 mg by injection under the skin, for example every 12 hours for 7 days in hospital studies, under medical supervision

When to expect effects

Not established; in hepatitis B trials the response tended to appear months after the 6-month course ended

Watch out for

Not FDA-approved and cannot be prescribed as an approved medicine in the US. Products sold online, including "research" vials, are unapproved and unverified, and FDA has said compounded thymosin alpha-1 may pose a significant risk of immune reactions (immunogenicity) and has complexities with peptide-related impurities, with inadequate safety information

What is it

Thymosin alpha-1 (thymalfasin) is not an FDA-approved drug and not a dietary supplement: Drugs@FDA lists no approved product that contains it, and any vial sold online as "thymosin alpha-1" or "TA-1", including products labeled for research, is unapproved and of unverified purity and strength. It is a synthetic 28-amino-acid peptide, a synthetic version of an immune signaling substance first found in the thymus; in trials it is given by injection under the skin. Outside the US it has been sold under the brand name Zadaxin: a 2002 drug-profile review listed approvals for chronic hepatitis B (and in some countries hepatitis C) in places including China, India, Mexico, Argentina, Peru, the Philippines, Singapore, Thailand and Venezuela, and a 2009 review by a researcher involved in its development said it was approved in over 35 countries. These are older reviews, not a current list, and we could not confirm which approvals are in force today on any regulator's website. In the US it has only been tested in clinical trials, including a phase 1 study, still recruiting in 2026, of whether it boosts COVID-19 vaccine responses in adults aged 65 and older (NCT06821100).

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You qualify for a registered clinical trial of thymalfasin and want to take part under the study team's supervision
You have chronic hepatitis B, a weakened immune system or cancer and want to ask your doctor which approved treatments fit you and whether any trial is open

Probably skip if…

You are thinking of buying "thymosin alpha-1" or "TA-1" vials online: they are unapproved, their contents are unverified, and you would be injecting an unknown product
You want general immune support, faster recovery or anti-aging effects, which no trial has tested
You hope it will replace treatment for sepsis, hepatitis or cancer: the largest sepsis and pancreatitis trials found no benefit on their main outcomes

Evidence at a glance

sepsis

Good Evidence
Effect
None in the largest trial (23.4% vs 24.1% died by day 28)
Best fit
Not established; possible subgroup effects (for example in diabetes or cancer) need their own trials
Time
Measured at 28 days

severe acute necrotizing pancreatitis

Good Evidence
Effect
None significant (15.7% vs 18.1% developed infected necrosis)
Best fit
Not established
Time
Measured during the hospital stay

chronic hepatitis B

Limited Evidence
Effect
Delayed; better virological and liver enzyme responses 6 months after stopping than interferon, not during treatment
Best fit
Adults with chronic hepatitis B in older trials, mostly HBeAg-negative
Time
Responses appeared after the 6-month course ended

cancer, alongside chemotherapy

Limited Evidence
Effect
Uncertain; trends toward longer survival that were not statistically significant
Best fit
Adults with cancer in clinical trials, alongside standard treatment
Time
Measured over 12 to 24 months in the melanoma trial

COVID-19

Mixed Evidence
Effect
Uncertain; lower mortality in pooled, highly inconsistent studies
Best fit
Hospitalized adults with moderate to critical COVID-19 in the studies pooled
Time
Measured during hospital treatment

Evidence for 5 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

sepsis

No benefit found
Good Evidence

In the TESTS trial, a double-blind, placebo-controlled phase 3 study at 22 centers in China, 1,106 adults aged 18 to 85 with sepsis were randomly assigned to thymosin alpha-1 1.6 mg or placebo injections every 12 hours for 7 days, and 1,089 who received at least one dose were analyzed. Deaths from any cause by day 28 were 23.4% with thymosin alpha-1 and 24.1% with placebo (hazard ratio 0.97 after a 2025 correction of the trial data), and no secondary or safety outcome differed. Subgroup results hinted at differences by age and diabetes, but these were exploratory. The trial was funded by Sun Yat-sen University, a Guangdong research center and SciClone Pharmaceuticals, which sells thymosin alpha-1. A 2025 meta-analysis of 11 trials found fewer deaths overall (odds ratio 0.73), yet no benefit when it was limited to high-quality or multicenter trials.

Effect size
None in the largest trial (23.4% vs 24.1% died by day 28)
Time to effect
Measured at 28 days
Best fit
Not established; possible subgroup effects (for example in diabetes or cancer) need their own trials
Less likely
Adults with sepsis in general, in whom the largest trial found no effect on survival

Bottom line: In the largest, best-designed trial, thymosin alpha-1 did not help adults with sepsis survive.

Evidence is mixed

A 2025 meta-analysis of 11 randomized trials reported lower 28-day mortality overall, but the benefit disappeared in high-quality and multicenter trials, and the authors said the total number of patients studied is still too small.

severe acute necrotizing pancreatitis

No benefit found
Good Evidence

In a double-blind, placebo-controlled trial at several Chinese centers, 508 patients with predicted severe acute necrotizing pancreatitis (94.3% needed intensive care) received thymosin alpha-1 1.6 mg every 12 hours for 7 days and then once daily for 7 days, or placebo. Infection of the dead pancreatic tissue, the main outcome, occurred in 15.7% versus 18.1%, a difference that was not statistically significant. New organ failure, bleeding and fistula rates also did not differ. Several authors reported fees from SciClone Pharmaceuticals.

Effect size
None significant (15.7% vs 18.1% developed infected necrosis)
Time to effect
Measured during the hospital stay
Best fit
Not established
Less likely
Patients with predicted severe necrotizing pancreatitis, the group studied

Bottom line: Thymosin alpha-1 did not prevent infection in severe pancreatitis.

chronic hepatitis B

Biomarker support
Limited Evidence

A 2008 meta-analysis pooled 4 small randomized trials (199 patients, mostly HBeAg-negative) comparing thymosin alpha-1 with interferon alpha for 6 months. At the end of treatment, thymosin alpha-1 did no better and on the combined response measure did worse (odds ratio 0.54). Six months after treatment stopped, responses favored thymosin alpha-1 (odds ratio 3.71 for virological response and 2.69 for complete response). The trials were small and are older than today's standard oral antiviral drugs, which were not the comparison.

Effect size
Delayed; better virological and liver enzyme responses 6 months after stopping than interferon, not during treatment
Time to effect
Responses appeared after the 6-month course ended
Best fit
Adults with chronic hepatitis B in older trials, mostly HBeAg-negative
Less likely
People expecting it to replace current antiviral treatment, which these trials did not compare

Bottom line: Small older trials suggest a delayed effect in hepatitis B; it has not been tested against today's standard drugs.

cancer, alongside chemotherapy

Disease adjunct
Limited Evidence

A 2011 Cochrane review found 6 trials of synthetic thymic peptides (thymopentin or thymosin alpha-1) added to chemotherapy or radiotherapy in adults with cancer. For thymosin alpha-1, the pooled result showed a trend toward fewer deaths that was not statistically significant (risk ratio 1.21 for survival, P = 0.14), and most trials had at least a moderate risk of bias. In the largest single trial, 488 people with metastatic melanoma were randomly assigned to five groups, all given dacarbazine chemotherapy: thymosin alpha-1 at 1.6, 3.2 or 6.4 mg with interferon alfa, thymosin alpha-1 at 3.2 mg without interferon, or interferon alfa alone (the control group). The two 3.2 mg groups had 10 and 12 tumor responses versus 4 in the control group. Median survival was 9.4 months in all patients given thymosin alpha-1 versus 6.6 months in the control group, a difference that did not reach statistical significance (hazard ratio 0.80, P = 0.08).

Effect size
Uncertain; trends toward longer survival that were not statistically significant
Time to effect
Measured over 12 to 24 months in the melanoma trial
Best fit
Adults with cancer in clinical trials, alongside standard treatment
Less likely
Anyone using it in place of cancer treatment, which no trial tested

Bottom line: Possible but unproven help alongside chemotherapy; trials have not shown a clear survival benefit.

COVID-19

Disease adjunct
Mixed Evidence

A 2023 meta-analysis pooled 8 studies of adults hospitalized with moderate to critical COVID-19 and found lower mortality with thymosin alpha-1 (risk ratio 0.59), but results varied widely between studies (I squared 84%), there was no difference in the need for a ventilator or in hospital stay, and the authors said randomized trials were still needed to confirm it.

Effect size
Uncertain; lower mortality in pooled, highly inconsistent studies
Time to effect
Measured during hospital treatment
Best fit
Hospitalized adults with moderate to critical COVID-19 in the studies pooled
Less likely
People seeking to prevent or treat mild infection at home, which was not studied

Bottom line: Weak, inconsistent evidence in hospitalized COVID-19; not confirmed by large randomized trials.

How it works

Thymosin alpha-1 is an immune modulator. In laboratory studies it influences how T cells mature and how much of certain signaling proteins (Th1 cytokines such as interferon-gamma and interleukin-2) they release, and it activates natural killer cells. That is why it has been tested in conditions where the immune system is thought to be weakened or out of balance: chronic hepatitis B, severe infections and sepsis, severe pancreatitis, cancer alongside chemotherapy, and COVID-19. A plausible mechanism is not the same as a proven benefit. In the two largest double-blind trials, in sepsis and in severe pancreatitis, it did not improve the main outcome. Most of the positive studies are small, open-label or from a single country, and none tested the uses sellers promote online, such as general immune support, faster recovery or anti-aging.

How to take it

1. Typical dose
There is no approved or established dose in the US, and this page does not recommend any dose. The hepatitis B trials pooled in a 2008 meta-analysis lasted 6 months. In a trial in severe pancreatitis, participants received 1.6 mg injected under the skin every 12 hours for 7 days, then 1.6 mg once a day for 7 more days. In the large sepsis trial, participants received 1.6 mg under the skin every 12 hours for 7 days.
2. Higher studied dose
A metastatic melanoma trial tested 1.6, 3.2 and 6.4 mg alongside chemotherapy and interferon. A US vaccine study (NCT06821100) gives 4.8 mg (three 1.6 mg injections) on day 0, or on days 0 and 3, before a COVID-19 booster. These are research doses, not recommendations.
3. Timing
Not established outside trial protocols
4. With food
Not applicable: it is given by injection
5. Split dosing
Not established; the hospital trials gave injections every 12 hours, and one then gave them once a day
6. How long to try
Trial courses ranged from 7 to 14 days in hospital studies to 6 months in hepatitis B. There are no long-term safety data for repeated self-administered courses

What to track

If you are in a trial, report every side effect to the study team
Redness, swelling or pain where it was injected, rash, hives or trouble breathing (allergic reaction: get urgent care)
Fever, chills or worsening illness, which need medical care rather than more injections

Bottom line: No approved dose exists; trials used 1.6 mg injections on study-specific schedules under medical supervision.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

In the large sepsis trial, no safety outcome differed between thymosin alpha-1 and placeboIn the severe pancreatitis trial, bleeding was reported in 6.3% versus 3.5% on placebo, a difference that was not statistically significantInjection-site reactions are possible with any injected product; trial papers we read did not report rates for them

Serious risks

  • Immune reactions and impurities in compounded or unregulated products: FDA has said compounded drugs containing thymosin alpha-1 may pose significant risk for immunogenicity (the body reacting against the peptide) for certain routes of administration and may have complexities with regard to peptide-related impurities and characterization of the active ingredient, and that the safety information is inadequate for the agency to sufficiently understand the extent of any safety issues. FDA lists it among substances whose nominations for compounding were later withdrawn.

  • Unknown contents: there is no FDA-approved thymosin alpha-1 product in the US, so vials sold online (including those labeled for research) have no verified identity, dose, sterility or purity. FDA says compounding from bulk drug substances (raw active ingredients) presents risks to patients and urges even licensed compounders to know their supplier.

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: we found no human data on thymosin alpha-1 in pregnancy, and FDA has said the safety information for it is inadequate. Breastfeeding: we found no data on whether it passes into breast milk. Anyone who is pregnant, could become pregnant or is breastfeeding should talk with their doctor before considering it, including in a trial.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

In the US, the only verified way to receive thymalfasin is inside a registered clinical trial, where the study team supplies and tracks the product
A label that says "for research use only" does not make a vial approved or verified: there is no US-approved thymosin alpha-1 product to compare it with

Be skeptical of…

"FDA-approved" thymosin alpha-1: no US-approved product exists
"For research use only" or "not for human consumption" vials marketed to people who plan to inject them
"Boosts immunity", "prevents colds and flu" or "anti-aging": no trial has tested these uses
"Cures" or "treats" hepatitis, cancer, long COVID or sepsis: the largest sepsis and pancreatitis trials were negative, and other results are unconfirmed
"No side effects" or "completely safe": FDA has said the safety information is inadequate

Frequently asked questions

Is thymosin alpha-1 FDA-approved?⌄

No. Drugs@FDA lists no approved product containing it, and it is not a dietary supplement. It has been sold under the brand Zadaxin in other countries, mainly for hepatitis B; reviews from 2002 and 2009 described approvals in many countries in Asia and Latin America, but those are older lists and we could not confirm the current approvals on a regulator's website. In the US it is only available in clinical trials.

Is it legal to buy thymosin alpha-1 online?⌄

Products sold online as thymosin alpha-1 or TA-1 are not FDA-approved drugs, and labeling a vial for research does not make it approved or verified for people. FDA lists thymosin alpha-1 among substances it had flagged for significant safety risks in compounding (immune reactions and impurities) whose nominations for its compounding lists were later withdrawn. Talk with your doctor before using any product like this.

Does thymosin alpha-1 boost the immune system?⌄

It changes immune cell activity in laboratory studies, but that has not translated into clear benefits in the largest human trials. In 1,089 adults with sepsis it did not lower deaths, and in 508 patients with severe pancreatitis it did not prevent infection. No trial has tested it for general immune support in healthy people.

Does it help with long COVID or COVID-19?⌄

A 2023 meta-analysis of hospitalized patients with moderate to critical COVID-19 found lower deaths, but the studies disagreed widely and the authors called for randomized trials. We found no published trial in long COVID. A US phase 1 study (NCT06821100) is testing whether it improves COVID-19 booster responses in adults aged 65 and older; it was still recruiting in 2026 and has posted no results.

Can I take it with my supplements or medicines?⌄

No interaction studies have been published, and this page lists no known interactions, which is not the same as proof of safety. Anyone taking other medicines, including cancer treatment or medicines that affect the immune system, should have a doctor or pharmacist review their full list before any use, including in a trial.

References by claim

sepsis

Wu et al., 2025 · PMC (2025) link

PMID 40447307 · PMC (2025) link

Gu et al., 2025 · PMC (2025) link

severe acute necrotizing pancreatitis

Ke et al., 2022 · PMC (2022) link

chronic hepatitis B

Yang et al., 2008 · PubMed (2008) link

cancer, alongside chemotherapy

Wolf et al., 2011 · PMC (2011) link

Maio et al., 2010 · PubMed (2010) link

COVID-19

Soeroto et al., 2023 · PubMed (2023) link

Safety

Certain bulk drug substances for use in compounding that may present significant safety risks · U.S. Food and Drug Administration link

Bulk drug substances used in compounding · U.S. Food and Drug Administration link

Track Thymosin Alpha-1 with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research (much of it preclinical or early-stage), not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.